Mosquirix (RTS,S) / GSK - LARVOL DELTA

Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission. (PubMed, Small) - "The Pfs47-RTS,S-BP formulation also achieves 80.4% protection against mosquito bite challenge and 68.15% transmission-reducing activity, demonstrating strong potential as a robust, dual-stage malaria vaccine candidate. Overall, this work underscores the potential of Pfs47‑RTS, S‑BP to overcome key limitations of current vaccines and to substantially advance global malaria control efforts."

Journal • Infectious Disease • Malaria

Assessing the potential impact of the RTS,S/ASO1 vaccine on malaria burden in Benin: a mathematical modelling approach. (PubMed, Malar J) - "These findings support policy efforts to integrate RTS,S/AS01 into Benin's Expanded Programme on Immunisation (EPI) and highlight the importance of continuous surveillance to monitor vaccine performance under real-world conditions."

Journal • Infectious Disease • Malaria

Final results from a phase IIb randomised controlled trial assessing the efficacy and impact of full- and fractional-dose regimens of the RTS,S/AS01E malaria vaccine in Ashanti Region, Ghana and Siaya County, Kenya, September 2019 - November 2024 (ESCMID Global 2026) - No abstract available

Clinical • P2b data • Infectious Disease • Malaria

The Cost and Budget Impact of Malaria Vaccine Introduction in Uganda. (PubMed, Value Health Reg Issues) - "Implementing the malaria vaccine would lead to significant increase in Uganda's immunization budget and the overall health sector budgets. To ensure sustainability, the government should prioritize funding and adopt cost-effective strategies, such as targeting high-transmission areas and expanding prevention efforts, to maintain affordability and achieve long-term success."

HEOR • Journal • Infectious Disease • Malaria

Malaria immunity in the infant: progress and pitfalls. (PubMed, Curr Opin Immunol) - "The successful development and ongoing rollout of the first malaria vaccines, RTS,S/AS01E and R21/Matrix-M, have injected much-needed optimism into the malaria prevention field...Here, we review key aspects of the epidemiology and biology of P. falciparum infection in the fetus and infant, highlight recent findings regarding age-related differences in the immune response, and summarize current vaccination approaches in this vulnerable population. We discuss how emerging mechanistic insights might inform optimal deployment of existing preventive tools and guide development of next-generation strategies to protect infants from malaria."

Journal • Review • Infectious Disease • Malaria

Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study. (PubMed, Malar J) - "A fourth dose delivered between 15- and 21-months of age (corresponding to a 6-12 month interval after the third dose) with high population coverage will likely avert the largest proportion of cases of uncomplicated malaria, severe malaria, and deaths in perennial settings, across transmission intensities. Therefore, the delivery of the fourth dose of the RTS,S/AS01 vaccine can be tailored to country-specific context and linked to existing health touchpoints to ensure adequate coverage of this dose to optimize its impact."

Journal • Infectious Disease • Malaria

Provincial stratification and equity-weighted cost-effectiveness of malaria vaccines in Zambia under climate variability. (PubMed, BMJ Public Health) - "RTS,S is borderline cost-effective at current prices, while R21 is highly cost-effective and potentially dominant. Findings support phased provincial deployment with equity weighting, budget integration and climate-adaptive investment to maximise health gains."

HEOR • Journal • Infectious Disease • Malaria

Comparison of the Efficacy of Cell Wall Disruption Methods for Saccharomyces cerevisiae INVSc1 cells Expressing Toxoplasma gondii Recombinant ROP6 Protein. (PubMed, Protein Expr Purif) - "It supports post-translational glycosylation and is employed in several licensed vaccines, including hepatitis B (Engerix-B), human papillomavirus (Gardasil), and malaria (Mosquirix). Although Y-PER reagent yielded lower amounts of rROP6 protein compared to microfluidizer and acid-washed glass bead methods, it provided good protein stability by reducing multimerization and degradation and offered operational simplicity. Overall, the choice of disruption method should be guided by the target protein's characteristics, production scale, and cost considerations to optimize yield and stability."

Journal • Hepatitis B • Infectious Disease • Inflammation • Malaria • Oncology • Targeted Protein Degradation

Knowledge, attitudes and factors associated with the awareness of caregivers of under-five children regarding the malaria vaccine in the Tiko Health District, Cameroon: A community-based cross-sectional study. (PubMed, PLOS Glob Public Health) - "The introduction of malaria vaccines, including RTS,S/AS01 (Mosquirix) and the recently WHO-recommended R21/Matrix-M, offers renewed hope for reducing malaria morbidity and mortality. Caregivers in the Tiko Health District exhibited limited knowledge and generally negative attitudes toward the malaria vaccine. Strengthening health-worker engagement, improving communication during routine immunization services, and addressing gaps in caregivers' understanding may enhance malaria vaccine uptake in the district."

Journal • Observational data • Infectious Disease • Malaria

TEpiNom: A computational framework integrating population data to prioritize plasmodium falciparum T cell epitopes. (PubMed, Vaccine) - "Together, this study presents TEpiNom for the systematic prioritization of T cell epitopes and epitope-dense regions, to streamline preclinical malaria vaccine development by refining computational predictions into experimentally tractable candidates. The framework is adaptable for vaccine development against other diverse and evasive pathogens."

Journal • Infectious Disease • Malaria • CD4 • CD8

CROSS-SECTIONAL HEALTH CENTRE AND COMMUNITY-BASED EVALUATION OF THE IMPACT OF THE MALARIA RTS,S/AS01 VACCINE ON PNEUMOCOCCAL ANTIMICROBIAL RESISTANCE IN MALAWIAN CHILDREN (ISPPD 2026) - No abstract available

Clinical • Infectious Disease • Malaria • Pneumococcal Infections

EPI-MAL-003: A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa (clinicaltrials.gov) - P=N/A | N=77953 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Malaria

The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments. (PubMed, Pathogens) - "Recent advances in vaccines, notably RTS,S/AS01 and R21/Matrix-M, represent landmark achievements, with large-scale rollouts demonstrating reductions in severe disease and mortality...However, challenges remain in ensuring equitable access, sustaining efficacy in the face of evolving parasite and vector biology, and integrating interventions into diverse health systems. This review highlights the need for adaptive, multifaceted approaches to achieve malaria elimination goals."

Journal • Review • Infectious Disease • Malaria

Advancing global health access through market shaping: Cases and learnings. (PubMed, PLOS Glob Public Health) - "We review examples including dolutegravir, rifapentine-based tuberculosis preventive therapy, pretomanid for drug-resistant tuberculosis, the RTS,S malaria vaccine, and Rwanda's hepatitis C program, alongside ecosystem-level interventions such as revolving funds and initiatives to strengthen regional manufacturing. Across these cases, we suggest generalizable lessons and describe trade-offs related to donor dependence, supplier concentration, and timing of interventions. The paper identifies priorities for empirical research to assess the performance, risks, and applicability of market shaping tools as global health needs and resource environments evolve."

Journal • Review • Hepatitis C • Infectious Disease • Inflammation • Malaria • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Uptake of malaria vaccine (RTS,S/AS01) among children aged 6-24 months: A cross-sectional survey conducted in the Western region of Cameroon, 1 year following the vaccine introduction. (PubMed, PLOS Glob Public Health) - "More than a year after the malaria vaccine introduction in the health districts of Foumbot and Foumban, the performance indicators for this vaccination are below expectations for the vaccine to have a significant impact on reducing malaria morbidity in children. Communicating to positively influence caregivers' perceptions of malaria vaccination is expected to contribute to improving the situation."

Journal • Infectious Disease • Malaria

Ensuring the Public Health Impact of Malaria Vaccination in High-Transmission Settings. (PubMed, Am J Trop Med Hyg) - "Results from RTS,S pilot implementation and seasonal administration for both vaccines are promising, but study designs have thus far precluded the identification of similar periods of negative efficacy. Because we expect delayed malaria cases of unknown severity in vaccinated individuals during implementation in high-transmission settings, we recommend enhanced surveillance and interventions that supplement malaria vaccination to strengthen prevention."

Journal • Infectious Disease • Malaria

Need for Real-World Evaluation of Malaria Vaccines and Reliable Vaccination Records in Africa. (PubMed, Am J Trop Med Hyg) - "However, both designs require accurate, individual-level vaccination data, which remains a major challenge in many African countries. Strengthening electronic immunization registries, alongside continued efforts to improve the quality and completeness of paper-based immunization records, is essential in African countries, not only for the evaluation of current vaccines such as RTS,S/AS01 and R21/Matrix-M, but also in preparation for future malaria vaccines, to support robust vaccine monitoring and decision-making."

HEOR • Journal • Real-world evidence • Infectious Disease • Malaria

Complexity of Infection and Plasmodium falciparum Circumsporozoite Protein Diversity Prior to Malaria Vaccine Implementation in Kaelé Health District, Cameroon, 2022-2023. (PubMed, medRxiv) - "The presence of vaccine-matched strains and high diversity in TH2/TH3 epitopes in csp may influence vaccine efficacy. Continued molecular surveillance is essential to monitor antigenic shifts and guide future strategies."

Journal • Infectious Disease • Malaria

Malaria: a review on its current epidemiological status and management strategies. (PubMed, Malar J) - "This includes cross-border prevention and control efforts, expansion of seasonal malaria chemoprevention programmes, identification of molecular markers of resistance, development of novel antimalarial agents, and scaled-up implementation of vaccines such as RTS,S/AS01 and R21/Matrix-M. Implementation of approaches employed by countries such as China in malaria elimination and strengthening global-Africa cooperation in the fight against malaria could further accelerate progress. This review aims to provide a comprehensive overview of global malaria with a focus on Africa and global efforts toward the continent's malaria elimination goals."

Journal • Review • Infectious Disease • Malaria

Determinants of caregivers' acceptance of the malaria vaccine: The case of Bamenda and Bamenda III Health Districts in Cameroon. (PubMed, Public Health Pract (Oxf)) - "Malaria continues to be a major health burden in sub-Saharan Africa, prompting the introduction of malaria vaccines such as RTS,S/AS01 (Mosquirix™) and R21/Matrix-M to reduce disease incidence. To improve vaccine uptake, targeted health communication strategies should focus on enhancing information accuracy, engaging trusted health professionals, and leveraging mobile health tools. Strengthening community engagement and addressing misconceptions are essential to achieving higher vaccine coverage and advancing malaria control efforts, especially in the Bamenda and Bamenda III Health Districts."

Journal • Infectious Disease • Malaria

RTSS/PBO: RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi (clinicaltrials.gov) - P=N/A | N=1691 | Completed | Sponsor: Michigan State University | Recruiting ➔ Completed | N=3000 ➔ 1691

Enrollment change • Trial completion • Infectious Disease • Malaria

The Malaria Vaccine Implementation Programme study area in Ghana: results of a household survey prior to the introduction of the RTS,S/AS01 vaccine. (PubMed, Malar J) - "The pilot implementation and evaluation of the RTS,S malaria vaccine in Ghana was conducted in an area with substantial malaria transmission and illness, modest health-seeking behaviour and ITN use, and good EPI vaccine coverage. This study has established the baseline comparability between implementation and comparator areas, which serves as the foundation for future feasibility assessments."

Journal • Infectious Disease • Malaria

Assessing RTS, S malaria vaccine rollout perception in Cameroon: Sentiment analysis from X and facebook using hugging face. (PubMed, Health Informatics J) - "Background: The introduction of the RTS, S (Mosquirix®) malaria vaccine in Cameroon represents a significant public health milestone...Sentiment analysis can act as a real-time tool, offering policymakers valuable insights into public reactions and attitudes toward immunization and other health initiatives. These findings reveal significant public skepticism that must be addressed through evidence-based communication strategies focused on vaccine safety, efficacy data from pilot programs, and engagement with community leaders to counter misinformation."

Journal • Infectious Disease • Malaria

Awareness, perception and influences on uptake of the RTS,S/AS01 malaria vaccine among caregivers for children under 5 years in South West region, Cameroon. (PubMed, Malariaworld J) - "Enhanced community engagement and improved service delivery may support equitable uptake. The insights from this qualitative phase offer a foundation for further research within the wider mixed-methods project."

Journal • Infectious Disease • Malaria

Systematic review of mHealth and digital health interventions to improve childhood vaccination uptake in 19 Sub-Saharan African countries. (PubMed, PLoS One) - "As 19 SSA countries were targeted to begin rolling out the two new malaria vaccines (RTS,S/AS01 and R21/Matrix-M) in 2024, this systematic review aims to investigate which mHealth/DH interventions are most effective at increasing vaccination uptake (by assessing vaccination coverage and timeliness outcomes) in these countries...The findings offer evidence-based insights to guide the development and implementation of mHealth/DH interventions within SSA childhood immunisation programmes. While interventions with voice-based components appear particularly promising, the limited certainty of evidence demonstrates further high-quality, context-specific research is required to draw stronger conclusions."

Journal • Review • Infectious Disease • Malaria • Pertussis • Respiratory Diseases • Tetanus